Doconexent

References cover NAFLD epidemiology, diagnosis, and treatment in children, including randomized controlled trials and systematic reviews. Topics include prevalence, risk factors, therapeutic targets, and interventions like losartan, probiotics, and lifestyle modifications. Key studies assess the efficacy of vitamin E, metformin, and docosahexaenoic acid in pediatric NAFLD.

Recent Alzheimer’s and dementia research highlights include FDA approval of Alpha Cognition’s Zunveyl, failed phase 3 trials, legal issues for Cassava Sciences, and compassionate use of a new drug. CTAD conference data revealed anti-tau drugs' lack of efficacy, while Tiziana’s foralumab received FDA clearance for compassionate use. Eisai’s anti-tau drug E2814 showed potential in reducing biomarkers. Roche’s trontinemab and UCB’s beprenemab faced setbacks, and Athira’s Fosgonimeton failed in Phase 2/3. Gene therapy LX001 showed stabilization in amyloid levels and reduction in tau biomarkers. Symptomatic treatments like Zunveyl and Montelukast showed promise in managing memory symptoms.

CTAD 2024 in Madrid showcased updates on Alzheimer’s clinical research, including Eisai’s E2814, Nilotinib, Roche’s trontinemab, UCB’s beprenemab, Vaccinex’s pepinemab, intranasal insulin and empagliflozin, Cognition Therapeutics’ CT1812, Eli Lilly’s ceperognastat, high-dose DHA, Lexeo Therapeutics’ LX001, nabilone, dronabinol, and CBD, highlighting safety, tolerability, and potential efficacy in various stages of Alzheimer’s.

dsm-firmenich launches life'sDHA B54-0100, its most potent DHA oil, offering 620mg of omega-3s per serving, derived from algae for sustainability. The company also introduces life'sOMEGA O3020 to North America, an algal omega-3 with a standard EPA to DHA ratio, and plans to launch high-potency EPA ingredients in 2025.

Small Business Consulting Corp. awarded $99,999,999 for a production grade insights portal. Data Monitor Systems awarded $8,253,108 for deployment services. Schutt Industries awarded $53,680,993 for single axis chassis trailers. Leanne Duguay awarded $14,764,030 for powerhouse exciter units. SAAB Inc. awarded $13,512,696 for radar system support. Multiple shipyards awarded $11,000,000 for maintenance services. Northrop Grumman awarded $10,768,532 for silicon carbide transistor wafers. Ivyhill Technologies awarded $9,374,230 for call center support.

Aptamil KID C-SynB, containing Synbio+ (probiotics Bifidobacterium breve M-16V and prebiotics GOS/lcFOS), aims to restore gut dysbiosis in C-section-born children, supporting digestion, immune function, and overall health. Available in Malaysia since June, it is priced at RM68 for a 600g pack. Studies show it restores gut flora and supports immune development, reducing risks like asthma and obesity.